

# 9 REFERENCES

1. Kang, L.I., W.M. Mars, and G.K. Michalopoulos, *Signals and cells involved in regulating liver regeneration*. *Cells*, 2012. **1**(4): p. 1261-92.
2. Allan Tsung, D.A.G., *Gross and Cellular Anatomy of the Liver*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer US: New York, NY.
3. Robinson, M.W., C. Harmon, and C. O'Farrelly, *Liver immunology and its role in inflammation and homeostasis*. *Cell Mol Immunol*, 2016. **13**(3): p. 267-76.
4. Stolz, Z.K.J.M.C.D.B., *Ultrastructure of the Hepatocyte*, in *Textbook of Hepatology: From Basic Science to Clinical Practice*, J.P.B.M. Juan Rodés MD, Andres T. Blei MD, Jürg Reichen MD, Mario Rizzetto MD,, Editor. 2007, Blackwell Publishing Ltd.
5. Sabine Colnot, C.P., *Liver Zonation*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
6. Alejandro Soto-Gutierrez, N.N.-A., Naoya Kobayashi, *Hepatocytes*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
7. Treyer, A. and A. Musch, *Hepatocyte polarity*. *Compr Physiol*, 2013. **3**(1): p. 243-87.
8. Sato, K., et al., *Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances*. *Hepatology*, 2019. **69**(1): p. 420-430.
9. Gouw, A.S., A.D. Clouston, and N.D. Theise, *Ductular reactions in human liver: diversity at the interface*. *Hepatology*, 2011. **54**(5): p. 1853-63.
10. Sun, T., S. Annunziato, and J.S. Tchorz, *Hepatic ductular reaction: a double-edged sword*. *Aging (Albany NY)*, 2019. **11**(21): p. 9223-9224.
11. Dufour, J.F., *Biliary Epithelial Cells*, in *Textbook of Hepatology: From Basic Science to Clinical Practice*, J.P.B.M. Juan Rodés MD, Andres T. Blei MD, Jürg Reichen MD, Mario Rizzetto MD,, Editor. 2007: Blackwell Publishing Ltd.
12. Yoshiaki Mizuguchi, S.S., Kumiko Isse, John G. Lunz III, Anthony J. Demetris, *Biliary Epithelial Cells*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
13. Pinzani, M., *The Hepatic Stellate Cell*, in *Textbook of Hepatology: From Basic Science to Clinical Practice*, J.P.B.M. Juan Rodés MD, Andres T. Blei MD, Jürg Reichen MD, Mario Rizzetto MD,, Editor. 2007, Blackwell Publishing Ltd.
14. Blomhoff, R., et al., *Transport and storage of vitamin A*. *Science*, 1990. **250**(4979): p. 399-404.
15. Gandhi, C.R., *Stellate Cells*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
16. Gandhi, C.R., *Kupffer Cells*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
17. Jaeschke, H., *Kupffer Cells*, in *Textbook of Hepatology: From Basic Science to Clinical Practice*, J.P.B.M. Juan Rodés MD, Andres T. Blei MD, Jürg Reichen MD, Mario Rizzetto MD,, Editor. 2007, Blackwell Publishing Ltd.
18. Shah, D.S.V.H., *Liver Sinusoidal Endothelial Cells*, in *Textbook of Hepatology: From Basic Science to Clinical Practice*, J.P.B.M. Juan Rodés MD, Andres T. Blei MD, Jürg Reichen MD, Mario Rizzetto MD,, Editor. 2007, Blackwell Publishing Ltd.
19. Stolz, D.B., *Sinusoidal Endothelial Cells*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.

20. Dirk Raddatz, G.R., *Hepatic Carbohydrate Metabolism*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
21. Titchenell, P.M., M.A. Lazar, and M.J. Birnbaum, *Unraveling the Regulation of Hepatic Metabolism by Insulin*. Trends Endocrinol Metab, 2017. **28**(7): p. 497-505.
22. Gross, D.N., M. Wan, and M.J. Birnbaum, *The role of FOXO in the regulation of metabolism*. Curr Diab Rep, 2009. **9**(3): p. 208-14.
23. Zhang, W., et al., *FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression*. J Biol Chem, 2006. **281**(15): p. 10105-17.
24. Ramnanan, C.J., et al., *Physiologic action of glucagon on liver glucose metabolism*. Diabetes Obes Metab, 2011. **13 Suppl 1**: p. 118-25.
25. Lin, H.V. and D. Accili, *Hormonal regulation of hepatic glucose production in health and disease*. Cell Metab, 2011. **14**(1): p. 9-19.
26. Jiansheng Huang, J.B., Janardan K. Reddy, *Hepatic Lipid Metabolism*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.
27. Strable, M.S. and J.M. Ntambi, *Genetic control of de novo lipogenesis: role in diet-induced obesity*. Crit Rev Biochem Mol Biol, 2010. **45**(3): p. 199-214.
28. Horton, J.D., J.L. Goldstein, and M.S. Brown, *SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver*. J Clin Invest, 2002. **109**(9): p. 1125-31.
29. Filhoulaud, G., et al., *Novel insights into ChREBP regulation and function*. Trends Endocrinol Metab, 2013. **24**(5): p. 257-68.
30. Benhamed, F., et al., *The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans*. J Clin Invest, 2012. **122**(6): p. 2176-94.
31. Ducharme, N.A. and P.E. Bickel, *Lipid droplets in lipogenesis and lipolysis*. Endocrinology, 2008. **149**(3): p. 942-9.
32. Murphy, S., S. Martin, and R.G. Parton, *Lipid droplet-organelle interactions; sharing the fats*. Biochim Biophys Acta, 2009. **1791**(6): p. 441-7.
33. Walther, T.C. and R.V. Farese, Jr., *The life of lipid droplets*. Biochim Biophys Acta, 2009. **1791**(6): p. 459-66.
34. Zehmer, J.K., et al., *A role for lipid droplets in inter-membrane lipid traffic*. Proteomics, 2009. **9**(4): p. 914-21.
35. Listenberger, L.L., et al., *Triglyceride accumulation protects against fatty acid-induced lipotoxicity*. Proc Natl Acad Sci U S A, 2003. **100**(6): p. 3077-82.
36. Davidson, N.O. and G.S. Shelness, *APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation*. Annu Rev Nutr, 2000. **20**: p. 169-93.
37. Gibbons, G.F., et al., *Synthesis and function of hepatic very-low-density lipoprotein*. Biochem Soc Trans, 2004. **32**(Pt 1): p. 59-64.
38. Shelness, G.S. and J.A. Sellers, *Very-low-density lipoprotein assembly and secretion*. Curr Opin Lipidol, 2001. **12**(2): p. 151-7.
39. Rustaeus, S., et al., *Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation*. J Nutr, 1999. **129**(2S Suppl): p. 463S-466S.

40. Steinberg, S.J., et al., *Very long-chain acyl-CoA synthetases. Human "bubblegum" represents a new family of proteins capable of activating very long-chain fatty acids.* J Biol Chem, 2000. **275**(45): p. 35162-9.
41. Reddy, J.K. and T. Hashimoto, *Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system.* Annu Rev Nutr, 2001. **21**: p. 193-230.
42. Laffel, L., *Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes.* Diabetes Metab Res Rev, 1999. **15**(6): p. 412-26.
43. Bartlett, K. and S. Eaton, *Mitochondrial beta-oxidation.* Eur J Biochem, 2004. **271**(3): p. 462-9.
44. Wanders, R.J., E.G. van Grunsven, and G.A. Jansen, *Lipid metabolism in peroxisomes: enzymology, functions and dysfunctions of the fatty acid alpha- and beta-oxidation systems in humans.* Biochem Soc Trans, 2000. **28**(2): p. 141-9.
45. Desvergne, B. and W. Wahli, *Peroxisome proliferator-activated receptors: nuclear control of metabolism.* Endocr Rev, 1999. **20**(5): p. 649-88.
46. Yu, S., S. Rao, and J.K. Reddy, *Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis.* Curr Mol Med, 2003. **3**(6): p. 561-72.
47. Hashimoto, T., et al., *Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.* J Biol Chem, 2000. **275**(37): p. 28918-28.
48. Kersten, S., et al., *Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting.* J Clin Invest, 1999. **103**(11): p. 1489-98.
49. Leone, T.C., C.J. Weinheimer, and D.P. Kelly, *A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders.* Proc Natl Acad Sci U S A, 1999. **96**(13): p. 7473-8.
50. Omiecinski, C.J., et al., *Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.* Toxicol Sci, 2011. **120 Suppl 1**: p. S49-75.
51. Hart, S.N., et al., *Three patterns of cytochrome P450 gene expression during liver maturation in mice.* Drug Metab Dispos, 2009. **37**(1): p. 116-21.
52. Bellentani, S., *The epidemiology of non-alcoholic fatty liver disease.* Liver Int, 2017. **37 Suppl 1**: p. 81-84.
53. Blachier, M., et al., *The burden of liver disease in Europe: a review of available epidemiological data.* J Hepatol, 2013. **58**(3): p. 593-608.
54. Browning, J.D., et al., *Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.* Hepatology, 2004. **40**(6): p. 1387-95.
55. Cohen, J.C., J.D. Horton, and H.H. Hobbs, *Human fatty liver disease: old questions and new insights.* Science, 2011. **332**(6037): p. 1519-23.
56. Benedict, M. and X. Zhang, *Non-alcoholic fatty liver disease: An expanded review.* World J Hepatol, 2017. **9**(16): p. 715-732.
57. Petaja, E.M. and H. Yki-Jarvinen, *Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review.* Int J Mol Sci, 2016. **17**(5).
58. Araujo, A.R., et al., *Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future.* Liver Int, 2018. **38 Suppl 1**: p. 47-51.

59. Younossi, Z., et al., *Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis*. Hepatology, 2019. **69**(6): p. 2672-2682.
60. Parikh, N.D., et al., *Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States*. Hepatology, 2019. **70**(2): p. 487-495.
61. Malik, S.M., et al., *Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis*. Liver Transpl, 2009. **15**(12): p. 1843-51.
62. Turchinovich, A., et al., *Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders*. Front Physiol, 2018. **9**: p. 1256.
63. Buzzetti, E., M. Pinzani, and E.A. Tsochatzis, *The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)*. Metabolism, 2016. **65**(8): p. 1038-48.
64. Ipsen, D.H., J. Lykkesfeldt, and P. Tveden-Nyborg, *Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease*. Cell Mol Life Sci, 2018. **75**(18): p. 3313-3327.
65. Donnelly, K.L., et al., *Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease*. J Clin Invest, 2005. **115**(5): p. 1343-51.
66. Lambert, J.E., et al., *Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease*. Gastroenterology, 2014. **146**(3): p. 726-35.
67. Rao, M.S. and J.K. Reddy, *Peroxisomal beta-oxidation and steatohepatitis*. Semin Liver Dis, 2001. **21**(1): p. 43-55.
68. Videla, L.A. and P. Pettinelli, *Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity*. PPAR Res, 2012. **2012**: p. 107434.
69. Fabbrini, E., et al., *Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease*. Gastroenterology, 2008. **134**(2): p. 424-31.
70. Adiels, M., et al., *Overproduction of large VLDL particles is driven by increased liver fat content in man*. Diabetologia, 2006. **49**(4): p. 755-65.
71. Ota, T., C. Gayet, and H.N. Ginsberg, *Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents*. J Clin Invest, 2008. **118**(1): p. 316-32.
72. Zhang, X.Q., et al., *Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease*. World J Gastroenterol, 2014. **20**(7): p. 1768-76.
73. Kitade, H., et al., *Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments*. Nutrients, 2017. **9**(4).
74. Tessari, P., et al., *Hepatic lipid metabolism and non-alcoholic fatty liver disease*. Nutr Metab Cardiovasc Dis, 2009. **19**(4): p. 291-302.
75. Stefan, N., F. Schick, and H.U. Haring, *Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease*. N Engl J Med, 2014. **371**(23): p. 2236-7.
76. Kumashiro, N., et al., *Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease*. Proc Natl Acad Sci U S A, 2011. **108**(39): p. 16381-5.
77. Perry, R.J., et al., *The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes*. Nature, 2014. **510**(7503): p. 84-91.

78. Ter Horst, K.W., et al., *Hepatic Diacylglycerol-Associated Protein Kinase Cepsilon Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans*. Cell Rep, 2017. **19**(10): p. 1997-2004.
79. Malhi, H. and G.J. Gores, *Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease*. Semin Liver Dis, 2008. **28**(4): p. 360-9.
80. Song, M.J. and H. Malhi, *The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease*. Pharmacol Ther, 2019. **203**: p. 107401.
81. Mota, M., et al., *Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease*. Metabolism, 2016. **65**(8): p. 1049-61.
82. Svegliati-Baroni, G., et al., *Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease*. Free Radic Biol Med, 2019. **144**: p. 293-309.
83. Hirsova, P., et al., *Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis*. J Lipid Res, 2016. **57**(10): p. 1758-1770.
84. Leamy, A.K., et al., *Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells*. J Lipid Res, 2014. **55**(7): p. 1478-88.
85. Ariyama, H., et al., *Decrease in membrane phospholipid unsaturation induces unfolded protein response*. J Biol Chem, 2010. **285**(29): p. 22027-35.
86. Volmer, R., K. van der Ploeg, and D. Ron, *Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains*. Proc Natl Acad Sci U S A, 2013. **110**(12): p. 4628-33.
87. Kakisaka, K., et al., *Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis*. Am J Physiol Gastrointest Liver Physiol, 2012. **302**(1): p. G77-84.
88. Pagadala, M., et al., *Role of ceramides in nonalcoholic fatty liver disease*. Trends Endocrinol Metab, 2012. **23**(8): p. 365-71.
89. Pettus, B.J., C.E. Chalfant, and Y.A. Hannun, *Ceramide in apoptosis: an overview and current perspectives*. Biochim Biophys Acta, 2002. **1585**(2-3): p. 114-25.
90. Schwabe, R.F. and D.A. Brenner, *Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways*. Am J Physiol Gastrointest Liver Physiol, 2006. **290**(4): p. G583-9.
91. Romeo, S., et al., *Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease*. Nat Genet, 2008. **40**(12): p. 1461-5.
92. Eslam, M., L. Valenti, and S. Romeo, *Genetics and epigenetics of NAFLD and NASH: Clinical impact*. J Hepatol, 2018. **68**(2): p. 268-279.
93. Chalasani, N., et al., *Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease*. Gastroenterology, 2010. **139**(5): p. 1567-76, 1576 e1-6.
94. Speliotes, E.K., et al., *Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits*. PLoS Genet, 2011. **7**(3): p. e1001324.
95. Hernaez, R., *Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review*. Gastroenterol Hepatol, 2012. **35**(1): p. 32-41.
96. Abul-Husn, N.S., et al., *A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease*. N Engl J Med, 2018. **378**(12): p. 1096-1106.
97. Stender, S., et al., *Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci*. Nat Genet, 2017. **49**(6): p. 842-847.

98. Danford, C.J., Z.M. Yao, and Z.G. Jiang, *Non-alcoholic fatty liver disease: a narrative review of genetics*. J Biomed Res, 2018. **32**(5): p. 389-400.
99. Zeybel, M., et al., *Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease*. Clin Epigenetics, 2015. **7**: p. 25.
100. Murphy, S.K., et al., *Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease*. Gastroenterology, 2013. **145**(5): p. 1076-87.
101. Gerhard, G.S. and J.K. DiStefano, *Micro RNAs in the development of non-alcoholic fatty liver disease*. World J Hepatol, 2015. **7**(2): p. 226-34.
102. Csak, T., et al., *microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis*. Liver Int, 2015. **35**(2): p. 532-41.
103. Cheung, O., et al., *Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression*. Hepatology, 2008. **48**(6): p. 1810-20.
104. Lowey, B., et al., *Hepatitis C Virus Infection Induces Hepatic Expression of NF-kappaB-Inducing Kinase and Lipogenesis by Downregulating miR-122*. mBio, 2019. **10**(4).
105. Baulande, S., et al., *Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage*. J Biol Chem, 2001. **276**(36): p. 33336-44.
106. Wilson, P.A., et al., *Characterization of the human patatin-like phospholipase family*. J Lipid Res, 2006. **47**(9): p. 1940-9.
107. Kienesberger, P.C., et al., *Mammalian patatin domain containing proteins: a family with diverse lipolytic activities involved in multiple biological functions*. J Lipid Res, 2009. **50** Suppl: p. S63-8.
108. Fuchs, C.D., T. Claudel, and M. Trauner, *Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD*. Trends Endocrinol Metab, 2014. **25**(11): p. 576-85.
109. He, S., et al., *A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis*. J Biol Chem, 2010. **285**(9): p. 6706-15.
110. Bruschi, F.V., et al., *PNPLA3 expression and its impact on the liver: current perspectives*. Hepat Med, 2017. **9**: p. 55-66.
111. Huang, Y., et al., *A feed-forward loop amplifies nutritional regulation of PNPLA3*. Proc Natl Acad Sci U S A, 2010. **107**(17): p. 7892-7.
112. Pirazzi, C., et al., *PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells*. Hum Mol Genet, 2014. **23**(15): p. 4077-85.
113. Bruschi, F.V., et al., *The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells*. Hepatology, 2017. **65**(6): p. 1875-1890.
114. Pingitore, P., et al., *PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis*. Hum Mol Genet, 2016. **25**(23): p. 5212-5222.
115. Basu Ray, S., *PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease*. Adipocyte, 2019. **8**(1): p. 201-208.
116. Rydel, T.J., et al., *The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad*. Biochemistry, 2003. **42**(22): p. 6696-708.

117. Jenkins, C.M., et al., *Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities*. J Biol Chem, 2004. **279**(47): p. 48968-75.
118. Kumari, M., et al., *Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase*. Cell Metab, 2012. **15**(5): p. 691-702.
119. Lake, A.C., et al., *Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members*. J Lipid Res, 2005. **46**(11): p. 2477-87.
120. Pingitore, P., et al., *Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function*. Biochim Biophys Acta, 2014. **1841**(4): p. 574-80.
121. Huang, Y., J.C. Cohen, and H.H. Hobbs, *Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease*. J Biol Chem, 2011. **286**(43): p. 37085-93.
122. Pirazzi, C., et al., *Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro*. J Hepatol, 2012. **57**(6): p. 1276-82.
123. Li, J.Z., et al., *Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis*. J Clin Invest, 2012. **122**(11): p. 4130-44.
124. Luukkonen, P.K., et al., *Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease*. J Hepatol, 2016. **64**(5): p. 1167-1175.
125. Ruhanen, H., et al., *PNPLA3 mediates hepatocyte triacylglycerol remodeling*. J Lipid Res, 2014. **55**(4): p. 739-46.
126. Peter, A., et al., *PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans*. Diabetologia, 2014. **57**(10): p. 2103-7.
127. Mitsche, M.A., H.H. Hobbs, and J.C. Cohen, *Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets*. J Biol Chem, 2018. **293**(18): p. 6958-6968.
128. Chamoun, Z., et al., *PNPLA3/adiponutrin functions in lipid droplet formation*. Biol Cell, 2013. **105**(5): p. 219-233.
129. Mondul, A., et al., *PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity*. J Nutr, 2015. **145**(8): p. 1687-91.
130. Dubuquoy, C., et al., *Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes*. J Hepatol, 2011. **55**(1): p. 145-53.
131. Hao, L., et al., *Shifts in dietary carbohydrate-lipid exposure regulate expression of the non-alcoholic fatty liver disease-associated gene PNPLA3/adiponutrin in mouse liver and HepG2 human liver cells*. Metabolism, 2014. **63**(10): p. 1352-62.
132. Rotman, Y., et al., *The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease*. Hepatology, 2010. **52**(3): p. 894-903.
133. Liu, Y.L., et al., *Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma*. J Hepatol, 2014. **61**(1): p. 75-81.



134. Kotronen, A., et al., *A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans*. Diabetologia, 2009. **52**(6): p. 1056-60.
135. Krawczyk, M., et al., *Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease*. J Hepatol, 2011. **55**(2): p. 299-306.
136. Namjou, B., et al., *GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network*. BMC Med, 2019. **17**(1): p. 135.
137. Kantartzis, K., et al., *Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene*. Diabetes, 2009. **58**(11): p. 2616-23.
138. Speliotes, E.K., et al., *PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease*. Hepatology, 2010. **52**(3): p. 904-12.
139. Trepo, E., et al., *Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease*. J Hepatol, 2011. **55**(4): p. 906-12.
140. Stattermayer, A.F., et al., *Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations*. J Hepatol, 2015. **63**(1): p. 156-63.
141. Salameh, H., et al., *PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease*. World J Hepatol, 2016. **8**(35): p. 1584-1592.
142. Tian, C., et al., *Variant in PNPLA3 is associated with alcoholic liver disease*. Nat Genet, 2010. **42**(1): p. 21-3.
143. Valenti, L., et al., *Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis*. World J Gastroenterol, 2012. **18**(22): p. 2813-20.
144. Vigano, M., et al., *Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B*. Hepatology, 2013. **58**(4): p. 1245-52.
145. Dongiovanni, P., et al., *PNPLA3 I148M polymorphism and progressive liver disease*. World J Gastroenterol, 2013. **19**(41): p. 6969-78.
146. Cox, A.J., et al., *Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus*. Diabetes Metab, 2011. **37**(5): p. 452-5.
147. Hotta, K., et al., *Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease*. BMC Med Genet, 2010. **11**: p. 172.
148. Lin, Y.C., et al., *A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children*. J Pediatr, 2011. **158**(5): p. 740-4.
149. Valenti, L., et al., *Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease*. Hepatology, 2010. **51**(4): p. 1209-17.
150. Romeo, S., et al., *Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent*. Int J Obes (Lond), 2010. **34**(1): p. 190-4.

151. Zain, S.M., et al., *A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease*. Hum Genet, 2012. **131**(7): p. 1145-52.
152. Sookoian, S., et al., *A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity*. J Lipid Res, 2009. **50**(10): p. 2111-6.
153. Davis, J.N., et al., *Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption*. Am J Clin Nutr, 2010. **92**(6): p. 1522-7.
154. Nobili, V., et al., *Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents*. Genes Nutr, 2014. **9**(3): p. 392.
155. Barata, L., et al., *Insulin Resistance Exacerbates Genetic Predisposition to Nonalcoholic Fatty Liver Disease in Individuals Without Diabetes*. Hepatol Commun, 2019. **3**(7): p. 894-907.
156. Shen, J., et al., *PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease*. J Gastroenterol Hepatol, 2015. **30**(1): p. 139-46.
157. Sevastianova, K., et al., *Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans*. Am J Clin Nutr, 2011. **94**(1): p. 104-11.
158. Marzuillo, P., et al., *Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children*. J Hepatol, 2013. **59**(5): p. 1143-4.
159. Younossi, Z., et al., *Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention*. Nat Rev Gastroenterol Hepatol, 2018. **15**(1): p. 11-20.
160. Chen, W., et al., *Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease*. Hepatology, 2010. **52**(3): p. 1134-42.
161. Basantani, M.K., et al., *Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome*. J Lipid Res, 2011. **52**(2): p. 318-29.
162. BasuRay, S., et al., *The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation*. Hepatology, 2017. **66**(4): p. 1111-1124.
163. Smagris, E., et al., *Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis*. Hepatology, 2015. **61**(1): p. 108-18.
164. Wang, Y., et al., *PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice*. Hepatology, 2019. **69**(6): p. 2427-2441.
165. Luukkonen, P.K., et al., *Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids*. JCI Insight, 2019. **4**(16).
166. Bruschi, F.V., et al., *PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells*. Hepatol Commun, 2019. **3**(9): p. 1191-1204.
167. Dutta, A.K., *Adiponutrin (PNPLA3) in liver fibrogenesis: Is unaltered HepG2 cell line a better model system compared to murine models?* Med Hypotheses, 2015. **85**(6): p. 736-9.
168. Yildirim, S., *Induced Pluripotent Stem Cells*. 2012, New York, NY: Springer.

169. Takahashi, K. and S. Yamanaka, *Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors*. Cell, 2006. **126**(4): p. 663-76.
170. Liu, H., et al., *Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts*. Cell Stem Cell, 2008. **3**(6): p. 587-90.
171. Li, W., et al., *Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors*. Cell Stem Cell, 2009. **4**(1): p. 16-9.
172. Park, I.H., et al., *Reprogramming of human somatic cells to pluripotency with defined factors*. Nature, 2008. **451**(7175): p. 141-6.
173. Grandy, R., R.A. Tomaz, and L. Vallier, *Modeling Disease with Human Inducible Pluripotent Stem Cells*. Annu Rev Pathol, 2019. **14**: p. 449-468.
174. Warren, C.R., et al., *Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease*. Cell Stem Cell, 2017. **20**(4): p. 547-557 e7.
175. DeBoever, C., et al., *Large-Scale Profiling Reveals the Influence of Genetic Variation on Gene Expression in Human Induced Pluripotent Stem Cells*. Cell Stem Cell, 2017. **20**(4): p. 533-546 e7.
176. Pashos, E.E., et al., *Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci*. Cell Stem Cell, 2017. **20**(4): p. 558-570 e10.
177. Kimbrel, E.A. and R. Lanza, *Current status of pluripotent stem cells: moving the first therapies to the clinic*. Nat Rev Drug Discov, 2015. **14**(10): p. 681-92.
178. Lo, B. and L. Parham, *Ethical issues in stem cell research*. Endocr Rev, 2009. **30**(3): p. 204-13.
179. Benam, K.H., et al., *Engineered in vitro disease models*. Annu Rev Pathol, 2015. **10**: p. 195-262.
180. Yiangou, L., et al., *Human Pluripotent Stem Cell-Derived Endoderm for Modeling Development and Clinical Applications*. Cell Stem Cell, 2018. **22**(4): p. 485-499.
181. Kyffin, J.A., et al., *Impact of cell types and culture methods on the functionality of in vitro liver systems - A review of cell systems for hepatotoxicity assessment*. Toxicol In Vitro, 2018. **48**: p. 262-275.
182. Roy-Chowdhury, N., et al., *Hepatocyte-like cells derived from induced pluripotent stem cells*. Hepatol Int, 2017. **11**(1): p. 54-69.
183. Si-Tayeb, K., et al., *Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells*. Hepatology, 2010. **51**(1): p. 297-305.
184. Hannan, N.R., et al., *Production of hepatocyte-like cells from human pluripotent stem cells*. Nat Protoc, 2013. **8**(2): p. 430-7.
185. Rashid, S.T., et al., *Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells*. J Clin Invest, 2010. **120**(9): p. 3127-36.
186. Sampaziotis, F., et al., *Directed differentiation of human induced pluripotent stem cells into functional cholangiocyte-like cells*. Nat Protoc, 2017. **12**(4): p. 814-827.
187. Cayo, M.A., et al., *JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia*. Hepatology, 2012. **56**(6): p. 2163-71.

188. Sampaziotis, F., C.P. Segeritz, and L. Vallier, *Potential of human induced pluripotent stem cells in studies of liver disease*. *Hepatology*, 2015. **62**(1): p. 303-11.
189. Zhang, S., et al., *Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin*. *Hum Mol Genet*, 2011. **20**(16): p. 3176-87.
190. Yusa, K., et al., *Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells*. *Nature*, 2011. **478**(7369): p. 391-4.
191. Carpentier, A., et al., *Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model*. *J Clin Invest*, 2014. **124**(11): p. 4953-64.
192. Schwartz, R.E., et al., *Modeling hepatitis C virus infection using human induced pluripotent stem cells*. *Proc Natl Acad Sci U S A*, 2012. **109**(7): p. 2544-8.
193. Ouchi, R., et al., *Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids*. *Cell Metab*, 2019. **30**(2): p. 374-384 e6.
194. Coll, M., et al., *Generation of Hepatic Stellate Cells from Human Pluripotent Stem Cells Enables In Vitro Modeling of Liver Fibrosis*. *Cell Stem Cell*, 2018. **23**(1): p. 101-113 e7.
195. Takebe, T., et al., *Vascularized and functional human liver from an iPSC-derived organ bud transplant*. *Nature*, 2013. **499**(7459): p. 481-4.
196. Ortmann, D. and L. Vallier, *Variability of human pluripotent stem cell lines*. *Curr Opin Genet Dev*, 2017. **46**: p. 179-185.
197. Kilpinen, H., et al., *Common genetic variation drives molecular heterogeneity in human iPSCs*. *Nature*, 2017. **546**(7658): p. 370-375.
198. Cuomo, A.S.E., et al., *Single-cell RNA-sequencing of differentiating iPS cells reveals dynamic genetic effects on gene expression*. *Nat Commun*, 2020. **11**(1): p. 810.
199. Rouhani, F., et al., *Genetic background drives transcriptional variation in human induced pluripotent stem cells*. *PLoS Genet*, 2014. **10**(6): p. e1004432.
200. Gieseck, R.L., 3rd, et al., *Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture*. *PLoS One*, 2014. **9**(1): p. e86372.
201. Kim, J.H., et al., *Enhanced Metabolizing Activity of Human ES Cell-Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics*. *Toxicol Sci*, 2015. **147**(1): p. 190-206.
202. Ware, B.R., D.R. Berger, and S.R. Khetani, *Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes*. *Toxicol Sci*, 2015. **145**(2): p. 252-62.
203. Bell, C.C., et al., *Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease*. *Sci Rep*, 2016. **6**: p. 25187.
204. Vorrink, S.U., et al., *Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics*. *FASEB J*, 2017. **31**(6): p. 2696-2708.
205. Bell, C.C., et al., *Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study*. *Toxicol Sci*, 2018. **162**(2): p. 655-666.
206. Wang, H.X., et al., *CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery*. *Chem Rev*, 2017. **117**(15): p. 9874-9906.

207. Doudna, J.A. and E. Charpentier, *Genome editing. The new frontier of genome engineering with CRISPR-Cas9*. Science, 2014. **346**(6213): p. 1258096.
208. Patterson, A.G., M.S. Yevstigneyeva, and P.C. Fineran, *Regulation of CRISPR-Cas adaptive immune systems*. Curr Opin Microbiol, 2017. **37**: p. 1-7.
209. Sander, J.D. and J.K. Joung, *CRISPR-Cas systems for editing, regulating and targeting genomes*. Nat Biotechnol, 2014. **32**(4): p. 347-55.
210. Ma, Y., L. Zhang, and X. Huang, *Genome modification by CRISPR/Cas9*. FEBS J, 2014. **281**(23): p. 5186-93.
211. Agrotis, A. and R. Ketteler, *A new age in functional genomics using CRISPR/Cas9 in arrayed library screening*. Front Genet, 2015. **6**: p. 300.
212. Rees, H.A. and D.R. Liu, *Base editing: precision chemistry on the genome and transcriptome of living cells*. Nat Rev Genet, 2018. **19**(12): p. 770-788.
213. Ran, F.A., et al., *Genome engineering using the CRISPR-Cas9 system*. Nat Protoc, 2013. **8**(11): p. 2281-2308.
214. Bassett, A.R., *Editing the genome of hiPSC with CRISPR/Cas9: disease models*. Mamm Genome, 2017. **28**(7-8): p. 348-364.
215. Cardenas-Diaz, F.L., et al., *Modeling Monogenic Diabetes using Human ESCs Reveals Developmental and Metabolic Deficiencies Caused by Mutations in HNF1A*. Cell Stem Cell, 2019. **25**(2): p. 273-289 e5.
216. Zhang, Y., et al., *Patient iPSC-Derived Neurons for Disease Modeling of Frontotemporal Dementia with Mutation in CHMP2B*. Stem Cell Reports, 2017. **8**(3): p. 648-658.
217. Yumlu, S., et al., *Gene editing and clonal isolation of human induced pluripotent stem cells using CRISPR/Cas9*. Methods, 2017. **121-122**: p. 29-44.
218. Veres, A., et al., *Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing*. Cell Stem Cell, 2014. **15**(1): p. 27-30.
219. Suzuki, K., et al., *Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones*. Cell Stem Cell, 2014. **15**(1): p. 31-6.
220. Ben Jehuda, R., Y. Shemer, and O. Binah, *Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9*. Stem Cell Rev Rep, 2018. **14**(3): p. 323-336.
221. Kimberland, M.L., et al., *Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments*. J Biotechnol, 2018. **284**: p. 91-101.
222. Mout, R., et al., *Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing*. ACS Nano, 2017. **11**(3): p. 2452-2458.
223. Liang, X., et al., *Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection*. J Biotechnol, 2015. **208**: p. 44-53.
224. Liu, Y., et al., *Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy*. Clin Pharmacol Ther, 2017. **102**(1): p. 131-140.
225. Gutierrez-Camino, A., I. Martin-Guerrero, and A. Garcia-Orad, *PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort*. Clin Pharmacol Ther, 2017. **102**(6): p. 906.
226. Ramasamy, T.S., et al., *Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances*

- hepatocyte differentiation and functionality*. *Tissue Eng Part A*, 2013. **19**(3-4): p. 360-7.
227. Lauschke, V.M., et al., *3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications*. *Biotechnol J*, 2019. **14**(7): p. e1800347.
  228. Foty, R., *A simple hanging drop cell culture protocol for generation of 3D spheroids*. *J Vis Exp*, 2011(51).
  229. Baze, A., et al., *Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells*. *Tissue Eng Part C Methods*, 2018. **24**(9): p. 534-545.
  230. Eyster, K.M., *The membrane and lipids as integral participants in signal transduction: lipid signal transduction for the non-lipid biochemist*. *Adv Physiol Educ*, 2007. **31**(1): p. 5-16.
  231. Mantzaris, M.D., E.V. Tsianos, and D. Galaris, *Interruption of triacylglycerol synthesis in the endoplasmic reticulum is the initiating event for saturated fatty acid-induced lipotoxicity in liver cells*. *FEBS J*, 2011. **278**(3): p. 519-30.
  232. Pickhardt, P.J., et al., *Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications*. *AJR Am J Roentgenol*, 2014. **202**(4): p. 752-8.
  233. Yilmaz, Y., *Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?* *Aliment Pharmacol Ther*, 2012. **36**(9): p. 815-23.
  234. Ricchi, M., et al., *Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes*. *J Gastroenterol Hepatol*, 2009. **24**(5): p. 830-40.
  235. Abdelmagid, S.A., et al., *Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults*. *PLoS One*, 2015. **10**(2): p. e0116195.
  236. Feng, R., et al., *Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case - control study*. *Lipids Health Dis*, 2017. **16**(1): p. 165.
  237. Hyysalo, J., et al., *Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity*. *Diabetes*, 2014. **63**(1): p. 312-22.
  238. Tofté, N., et al., *Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes*. *Sci Rep*, 2019. **9**(1): p. 16398.
  239. Mousa, A., et al., *Lipidomic profiling reveals early-stage metabolic dysfunction in overweight or obese humans*. *Biochim Biophys Acta Mol Cell Biol Lipids*, 2019. **1864**(3): p. 335-343.
  240. Min, H.K., et al., *Metabolic profiling reveals that PNPLA3 induces widespread effects on metabolism beyond triacylglycerol remodeling in Huh-7 hepatoma cells*. *Am J Physiol Gastrointest Liver Physiol*, 2014. **307**(1): p. G66-76.
  241. Mancina, R.M., et al., *Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant*. *J Clin Endocrinol Metab*, 2015. **100**(5): p. E821-5.
  242. Franko, A., et al., *Dissociation of Fatty Liver and Insulin Resistance in I148M PNPLA3 Carriers: Differences in Diacylglycerol (DAG) FA18:1 Lipid Species as a Possible Explanation*. *Nutrients*, 2018. **10**(9).

243. Yahagi, N., et al., *A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids*. J Biol Chem, 1999. **274**(50): p. 35840-4.
244. Clarke, S.D. and D.B. Jump, *Dietary polyunsaturated fatty acid regulation of gene transcription*. Annu Rev Nutr, 1994. **14**: p. 83-98.
245. Maruyama, H., et al., *Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells*. Lipids Health Dis, 2014. **13**: p. 78.
246. Videla, L.A., et al., *Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease*. Free Radic Biol Med, 2004. **37**(9): p. 1499-507.
247. Zhang, Y., et al., *Effect of alpha-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes*. Lipids Health Dis, 2011. **10**: p. 122.
248. Olzmann, J.A. and P. Carvalho, *Dynamics and functions of lipid droplets*. Nat Rev Mol Cell Biol, 2019. **20**(3): p. 137-155.
249. Xia, J., et al., *MetaboAnalyst: a web server for metabolomic data analysis and interpretation*. Nucleic Acids Res, 2009. **37**(Web Server issue): p. W652-60.
250. Xia, J. and D.S. Wishart, *Metabolomic data processing, analysis, and interpretation using MetaboAnalyst*. Curr Protoc Bioinformatics, 2011. **Chapter 14**: p. Unit 14 10.
251. Slotte, J.P. and B. Ramstedt, *The functional role of sphingomyelin in cell membranes*. European Journal of Lipid Science and Technology, 2007. **109**(10): p. 977-981.
252. Tanaka, N., et al., *Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis*. J Clin Gastroenterol, 2008. **42**(4): p. 413-8.
253. Nogueira, M.A., et al., *Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial*. Clin Nutr, 2016. **35**(3): p. 578-86.
254. Takeuchi, Y., et al., *Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit*. J Biol Chem, 2010. **285**(15): p. 11681-91.
255. Yoshikawa, T., et al., *Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements*. J Biol Chem, 2002. **277**(3): p. 1705-11.
256. Thiam, A.R. and M. Beller, *The why, when and how of lipid droplet diversity*. J Cell Sci, 2017. **130**(2): p. 315-324.
257. Nakamura, M.T., et al., *Mechanisms of regulation of gene expression by fatty acids*. Lipids, 2004. **39**(11): p. 1077-83.
258. Clarke, S.D., et al., *Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors*. Am J Clin Nutr, 1999. **70**(4): p. 566-71.
259. *Appendix: Drug Metabolizing Enzymes and Biotransformation Reactions*, in *ADME-Enabling Technologies in Drug Design and Development*. p. 545-565.
260. Almazroo, O.A., M.K. Miah, and R. Venkataramanan, *Drug Metabolism in the Liver*. Clin Liver Dis, 2017. **21**(1): p. 1-20.
261. Udayan Apte, P.K., *Detoxification Functions of the Liver*, in *Molecular Pathology of Liver Diseases*, S.P.S. Monga, Editor. 2011, Springer, US: New York, NY.

262. Cobбина, E. and F. Akhlaghi, *Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters*. Drug Metab Rev, 2017. **49**(2): p. 197-211.
263. Lake, A.D., et al., *Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease*. Drug Metab Dispos, 2011. **39**(10): p. 1954-60.
264. Donato, M.T., et al., *Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts*. Drug Metab Dispos, 2006. **34**(9): p. 1556-62.
265. Massart, J., et al., *Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity*. J Clin Transl Res, 2017. **3**(Suppl 1): p. 212-232.
266. Woolsey, S.J., et al., *CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease*. Drug Metab Dispos, 2015. **43**(10): p. 1484-90.
267. Fisher, C.D., et al., *Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease*. Drug Metab Dispos, 2009. **37**(10): p. 2087-94.
268. Hardwick, R.N., et al., *Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease*. Drug Metab Dispos, 2013. **41**(3): p. 554-61.
269. Phielers, J., et al., *The role of the complement system in metabolic organs and metabolic diseases*. Semin Immunol, 2013. **25**(1): p. 47-53.
270. Bykov, I., et al., *Complement C3 contributes to ethanol-induced liver steatosis in mice*. Ann Med, 2006. **38**(4): p. 280-6.
271. Rensen, S.S., et al., *Activation of the complement system in human nonalcoholic fatty liver disease*. Hepatology, 2009. **50**(6): p. 1809-17.
272. Hong, F., et al., *Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-x(L) proteins*. Oncogene, 2002. **21**(1): p. 32-43.
273. Moyer, A.M., et al., *Acetaminophen-NAPQI hepatotoxicity: a cell line model system genome-wide association study*. Toxicol Sci, 2011. **120**(1): p. 33-41.
274. Liu, W., et al., *Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans*. Aging (Albany NY), 2016. **9**(1): p. 26-40.
275. Donati, B., et al., *The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage*. Hepatology, 2016. **63**(3): p. 787-98.
276. Das, K. and P. Kar, *Non-alcoholic steatohepatitis*. J Assoc Physicians India, 2005. **53**: p. 195-9.
277. Wruck, W., et al., *Concise Review: Current Status and Future Directions on Research Related to Nonalcoholic Fatty Liver Disease*. Stem Cells, 2017. **35**(1): p. 89-96.
278. Peverill, W., L.W. Powell, and R. Skoien, *Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation*. Int J Mol Sci, 2014. **15**(5): p. 8591-638.
279. Neuschwander-Tetri, B.A., *Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH*. Curr Gastroenterol Rep, 2010. **12**(1): p. 49-56.



280. Yamaguchi, K., et al., *Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis*. *Hepatology*, 2007. **45**(6): p. 1366-74.
281. Luukkonen, P.K., et al., *Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars*. *Diabetes Care*, 2018. **41**(8): p. 1732-1739.
282. Alasoo, K., et al., *Transcriptional profiling of macrophages derived from monocytes and iPS cells identifies a conserved response to LPS and novel alternative transcription*. *Sci Rep*, 2015. **5**: p. 12524.
283. Grompe, M. and S. Strom, *Mice with human livers*. *Gastroenterology*, 2013. **145**(6): p. 1209-14.
284. Bissig, K.D., et al., *P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity*. *Drug Metab Dispos*, 2018. **46**(11): p. 1734-1744.